Articles by tag: crispr-gene-therapy

CRISPR gene therapy for children with anemia: EMA approval 2026

EMA approved CASGEVY for children 5-11 years with sickle cell anemia. 100% efficacy, price 1.8 million EUR. Risks and benefits — in the analysis. Learn more.

Casgevy: CRISPR therapy approved by FDA | Breakthrough in treatment

FDA approved Casgevy — the first CRISPR gene therapy for sickle cell disease and beta-thalassemia. Learn how the breakthrough by Vertex and CRISPR Therapeutics is changing lives.